Explore the latest insights into global clinical trial trends, innovations, and strategies shaping the future of oncolytic virus therapy. Oncolytic virus therapies utilize genetically modified or ...

Oncolytic viruses are therapeutic agents used for in situ immunization in cancer immunotherapy. Unfortunately, its efficacy is particularly limited in solid tumors expressing stimulator of interferon ...

Oncolytic viruses (OVs) are viruses that infect and kill cancer cells while sparing healthy tissue, making them a promising therapeutic option in cancer ...

This flaw has prompted scientists to seek alternative solutions. One alternative to antibiotics is phage therapy, which harnesses viruses to attack bacterial cells. Conceived over a century ago ...

PHAXIAM Therapeutics (Euronext: PHXM - FR0011471135), a biopharmaceutical company (“PHAXIAM” or “the Company”) developing innovative ...

Daiichi Sankyo has launched its oncolytic virus therapy Delytact in Japan – its first world market – as a treatment for malignant glioma, an aggressive form of brain cancer. Delytact ...

Other proteins such as H-Ras and Rac1 have been shown to mediate oncolytic specificity in certain systems. The NDV genome allows for stable expression of foreign genes while avoiding the problem ...

Oncolytic Virus Therapy: Global Clinical Trial Landscape 2024. This comprehensive whitepaper analyzes the evolving landscape of oncolytic virus therapies (OVT), providing critical insights into ...

Thibaut du Fayet, Chief Executive Officer of PHAXIAM, stated: “We start 2025 with a clear ambition to position PHAXIAM as a Specialty Pharma in Critical care, in the booming phage therapy market.